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ABSTRACT 
Objective: To develop a rapid, simple and sensitive ultra-performance liquid chromatography and tandem mass spectrometry (UPLC-MS/MS) 
method for quantitative estimation of atenolol (ATN) in rat plasma and its application to pharmacokinetic drug-herb interaction study. 
Methods: Simple precipitation method was used for the extraction of plasma samples with an aliquot of 25 μl plasma samples extracted using 
acetonitrile precipitation technique containing internal standard. Chromatographic separation was performed using Phenomenex, Kinetex, C18, 50 
x 2.1 mm, 1.7µ by a gradient mixture of 0.1 % formic acid in acetonitrile and 10 mmol Ammonium formate as a mobile phase at the flow rate of 0.7 
ml/min. The analyte was protonated in the positive electrospray ionization (ESI) interface and detected in multiple reactions monitoring (MRM) 
modes using the transition m/z 145.0-267.2. 
Results: The developed method had an advantage of fast chromatography run time of 1.8 min with improved sensitivity over existing methods and 
broader application to use for drug-herb or drug-drug interaction studies in rat pharmacokinetic. Calibration curves have been linear over the wide 
range of 4.93-5047.00 ng/ml in rat plasma which covers a wide range of plasma concentrations form study samples. ATN is widely used as a 
biomarker for determination of the drug-herb or drug-drug interactions studies, especially with the drugs that alter the permeability of another 
administered drug(s) and the developed method can be used to explore drug interaction studies. Especially to evaluate the role of concurrently 
administered drugs and its impact on permeability enhancer or absorption enhancer drugs following oral dose administration. This method will be 
significantly useful for the drug-herb pharmacokinetic interaction studies where we cannot quantify the herb because of multiple components in the 
hydro-alcoholic or aqueous extract of any herb, so choice remained is to quantify ATN and therefore it will be extremely helpful in such scenario.  
Conclusion: It was concluded that the developed UPLC-MS/MS method was sensitive linear and rapid; can be used for quantification of ATN in rat 
plasma for pharmacokinetic drug-herb interaction study. 
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ATN is a biopharmaceutical classification system (BCS) class III drug 
(high solubility, low permeability) and is known as a marker of 
paracellular permeability. The absorption of ATN after oral 
administration is rapid but incomplete. Only about 50-60% is 
absorbed. Peak plasma concentrations of 300-800 ng/ml are seen at 
between 2-4 h after administration of a 100 mg dose in human. The 
effect of ATN on heart rate usually begins at one hour, peaks at 2-4 h 
and persists for 24 h. The antihypertensive effect also usually persists 
for 24 h. There is a linear correlation of heart rate, but not blood 
pressure, with plasma ATN concentrations in the range 0.02-200 
mcg/ml. ATN distributes readily into most tissues except for brain and 
cerebrospinal fluid. Approximately 5-15% binds to plasma protein. 
Elimination of ATN occurs mainly by renal excretion of unchanged 
medicine. Little or no metabolism occurs in the liver. The plasma half-
life is 6-7 h in patients with normal renal function. Considering the 
absorption, distribution, metabolism and excretion properties of ATN 
(a BCS class III drug; high solubility, low permeability) is used as a 
marker of paracellular permeability to evaluate bio-enhancer property 
of the administered drug or to evaluate drug-drug interactions (DDI) 
and drug-herb interactions (DHI) in various models [1, 3]. 
Bioenhancers are such agents, which when combined with an active 
drug lead to the potentiation of the pharmacologic effect of the drug 
by improving the blood levels. Such formulations have been found to 
increase the bioavailability/bio-efficacy of a number of drugs even 
when reduced doses of drugs are present in such formulations or in 
presence of the co-administered drug. Evidence has been obtained 
for such classes of drugs which are (a) poorly bioavailable and/or 
efficacious, (b) require prolonged therapy, and (c) are highly toxic 
and expensive. The development of the phytomolecules is based on 
ancient knowledge of Ayurveda. They augment the bioavailability or 
biological activity of drugs when administered at low doses. They 
reduce the dose; shorten the treatment period thus reducing drug-
resistance problems. The treatment is made cost-effective, 
minimizing drug toxicity and adverse reactions. When used in 
combination with the number of drug classes such as antibiotics, 
anti-tuberculosis, antiviral, antifungal and anti-cancer drugs they are 
quite effective. Oral absorption of vitamins, minerals, herbal 
extracts, amino acids and other nutrients are improved by them. 
They act through several mechanisms which may affect mainly 
absorption process, drug metabolism or action on drug-target [4, 5]. 
Bioanalytical methods of measuring drugs in biologic media are 
increasingly important to accurately quantitate drugs in biological 
fluids. Hence considering the wide application of ATN, the present 
study was planned and executed to describe method development 
using simple, specific, rapid and sensitive UPLC-MS/MS method for 
the determination of ATN in rat plasma.  
ATN, albendazole, K2EDTA, formic acid, and ammonium formate 
were obtained from Sigma-Aldrich (Bangalore, India). Acetonitrile 
from J. T. Baker (Mumbai, India). All other chemicals used in this 
study were of analytical grade. 
All animal studies had the approval of the institutional animal ethics 
committee (IAEC) as per approval number MPC/IAEC/02/2015 of 
“UKA Tarsadia University” (animal house facility) and were in 
accordance with the guidelines of the CPCSEA, Government of India. 
Animals were acclimatized in study rooms for at least three days 
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prior to dosing. Rats were housed in polypropylene cages (1 animals 
per cage, marked for identification) maintained in controlled 
environmental conditions (22±3 °C; 40-70% RH) with 12 h light and 
dark cycles. Rats were given rodent pellet diet, and UV treated 
filtered water ad libitum. Rat blood samples were collected using a 
serial sampling design (n=6 per time point; pre-dose, 0.25, 0.5, 1, 2, 
4, 6, 8 and 24 h) following oral dose administration to fed Sprague 
Dawley rats at 10 mg/kg dose.  
A standard stock solution of ATN and albendazole were prepared 
and were stored at 2-8 °C until use. The analytical standard for ATN 
in acetonitrile over a concentration range of 4.93 ng/ml to 5047.00 
ng/ml by serial dilution method and same concentration range for 
calibration curve were also prepared in blank rat plasma.  
An aliquot of 25 µl study sample or spiked calibration standard/ 
quality control sample was added to individual pre-labeled 
microcentrifuge tubes followed by 25 µl of IS prepared in water 
(albendazole, 500 ng/ml) was added except for blank rat plasma, 
where 25 µl of water was added. Samples were vortexed, followed 
by 100 µl of acetonitrile was added and samples were vortexed for 
another 5 min. After centrifugation of the samples at 10000 rpm for 
5 min at 4 °C, the supernatant was collected and 5 µl was injected 
onto the UPLC-MS/MS system.  
An AcquityTM UPLC (USA) consisting of flow control valve, vacuum 
degasser operated in a gradient mode to deliver the mobile phase at 
a flow rate of 0.7 ml/min. The chromatographic system consisted of 
phenomenex kinetex column (C18, 50 mm× 2.1 mm, 1.7 µm) and 
mobile phase consists of 0.1 % formic acid v/v/in acetonitrile (A), 10 
mmol ammonium formate in water (B). A gradient UPLC method 
with 1.8 min run time was employed for analysis. The flow rate was 
0.7 ml/min. Separation was achieved using phenomenex kinetex C18 
column, maintained at 45 °C employing an injection volume of 5 µl 
for in vivo rat samples.  
Mass spectrometric detection was performed on AB Sciex-4000 
triple quadrupole LC/MS/MS mass spectrometer equipped with ESI 
source, the MRM modes was used for data acquisition with Analyst 
1.6.2 software. Peak integration and calibration were carried out by 
using Analyst 1.6.2 software. MS and MS/MS condition for pure 
standards of ATN and IS albendazole were optimized by continuous 
infusion at 5 µl/min using syringe pump. The transitions monitored 
were m/z 267.2 (m/z)>145.0 and 266.1>234.0 for components ATN 
and IS albendazole, respectively. All analyzes were carried out in 
positive ion ESI with spray voltage set at 5500 V. The heated ESI 
temperature was set 550 °C. Nitrogen ion source gas GS1 and GS2 
set at 40 and 60 psi, respectively. The collision assisted dissociation 
(CAD) was used at pressure 6 psi. Total run time for UPLC-MS/MS 
analysis was 1.8 min. 
The method was successfully applied to evaluate the plasma 
concentration versus time profile of ATN in rat plasma following oral 
administration at 10 mg/kg dose of ATN. The oral dose volume was 10 
ml/kg and dosing was performed using oral gauge needle. The 
suspension formulation was prepared freshly on the day of dosing. 
Studies were performed in healthy male Sprague Dawley rats (200-
250 g). A serial sampling design was used (n=3 per time point). 
Approximately, 100 µl of blood samples was collected (K2EDTA 
anticoagulant, 20 μl of K2EDTA solution/ml of blood, 200 mmol) at 
0.25, 0.5, 1, 2, 4, 8 and 24 h post-dose. Plasma samples were separated 
by centrifugation of whole blood and stored below-70±10 °C until 
bioanalysis. 
Pharmacokinetic parameters were calculated using non-
compartmental analysis tool of WinNonlin® software (Version 7). 
The area under the concentration time curve (AUClast and AUCinf) was 
calculated by linear trapezoidal rule. The peak concentration (Cmax) 
and time for the peak concentration (Tmax) were the observed values.  
In order to find most, sensitive ionization mode for the components 
studied, ESI positive ion mode and ESI negative ion mode were tested 
with the various combination of mobile phase, i.e., methanol, 
acetonitrile and water/ammonium acetate buffer (2 mmol)/formic 
acid (0.1%) in positive and negative ionization mode. It was observed 
that the signal intensity for [M+H]+ions in ESI positive ion mode were 
7-14-fold higher for ATN using 0.1 % formic acid v/v/in acetonitrile 
and 10 mmol ammonium formate in water, versus experiments run 
with ESI negative ion mode. The protonated molecular ion of [M+H]+, 
m/z 267.2 were obtained for ATN. No significant solvent adduct ions 
or fragment ions were observed in the full scan spectra of ATN and 
albendazole (IS). Thus, it was decided to utilize positive ion mode for 
detection and quantification of [M+H]+ ions and representative 
chromatogram showed in the fig. 1 and 2. 
  
 
Fig. 1: Representative chromatograms of rat blank plasma using ATN and albendazole LC/MS/MS method 
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Fig. 2: Representative chromatograms of ATN and albendazole in rat plasma sample 
 
The next step was to develop the simple and efficient sample clean-
up devoid of matrix effect and interference from endogenous plasma 
components for estimation of ATN in rat plasma. Sample extraction 
method was like liquid-liquid extraction (LLE) was tried using ether 
and different combinations of hexane and ethyl acetate (80–20%, 
v/v), n-hexane and isopropyl alcohol (2–5%, v/v) was also tried but 
none of these was found suitable to give good and consistent 
recovery for ATN. Finally, precipitation method was tried with 100% 
acetonitrile and found suitable to give optimum recovery for ATN 
and internal standard. For determination of matrix effect, control 
drug-free plasma was extracted using the described method and 
drug was added in the extracted supernatant. Matrix effect was 
determined by comparing the analytical response of these samples 
with that of standard solutions. 
The method described above was successfully applied to a 
pharmacokinetic evaluation of ATN. Following oral administration of 
ATN at 10 mg/kg oral suspension formulation to male Sprague 
Dawley rats, plasma concentrations were quantifiable up to 24.00 h 
(last sampling point) with Tmax at 6.00 h. The plasma concentration-
time profile of ATN is shown in fig. 3 and mean pharmacokinetic 
parameters are presented in table 4. 
  
 
Fig. 3: Mean plasma concentration vs. time following a single dose oral administration of ATN in male sprague dawley rats 
 
Table 4: Mean pharmacokinetic parameters following single oral administration of ATN in male sprague dawley rats 
Analyte Tmax (h) Cmax (ng/ml) AUC(0-t) (h*ng/ml)  AUC(0-inf) (h*ng/ml)  
ATN 6.00±2.00 227.93±46.89 2811.62±120.51 2917.46±123.06 
Data of n=6 rats; mean±SD; AUC: area under the concentration-time curve; 0-t: zero to time; 0-inf: zero to infinity; Tmax: time to reach peak plasma 
concentrations; Cmax: peak plasma concentrations 
 
The UPLC-MS/MS bioanalytical method for determination of ATN was 
developed in rat plasma. The method was sensitive enough to detect 
low concentration of 4.93 ng/ml for ATN with a short run time of 1.8 
min. Recovery of ATN from the spiked control samples were>85% by 
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using convenient and the rapid precipitation method using 
acetonitrile. The method was successfully applied to generate the 
pharmacokinetic evaluation of ATN in rat plasma samples following 
oral dose administration and can be used to evaluate DHI or DDI 
interactions studies associated with permeability enhancer properties 
of herb drugs.  
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